Updates in Anthracycline-Mediated Cardiotoxicity.
Fiche publication
Date publication
janvier 2018
Journal
Frontiers in pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent
Tous les auteurs :
Nebigil CG, Désaubry L
Lien Pubmed
Résumé
Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion of cancer therapies and the short- and long-term quality of life. Anthracyclines are currently used to treat many cancers, including the various forms of leukemia, lymphoma, melanoma, uterine, breast, and gastric cancers. World Health Organization registered anthracyclines in the list of essential medicines. However, anthracyclines display a major cardiotoxicity that can ultimately culminate in congestive heart failure. Taking into account the growing rate of cancer survivorship, the clinical significance of anthracycline cardiotoxicity is an emerging medical issue. In this review, we focus on the key progenitor cells and cardiac cells (cardiomyocytes, fibroblasts, and vascular cells), focusing on the signaling pathways involved in cellular damage, and the clinical biomarkers in anthracycline-mediated cardiotoxicity.
Mots clés
anthracylines, biomarkers, cardiac damage, cardio-oncology, cardiotoxicity, chemotheraphy
Référence
Front Pharmacol. 2018 ;9:1262